Cell Therapeutics (CTIC) will reacquire the rights to Pixuvri and Opaxio from Novartis (NVS) on the condition that NVS receive "certain potential payments ... based on sales [and] any sublicens[ing]."
"Regaining full rights to these two anti-cancer agents ... provides us with the flexibility to manage these assets within the context of our overall product portfolio strategy," CTIC CEO James Bianco says. (PR)
Recently: CTiC rallies on NICE nod for Pixuvri
CTIC +12% premarket